Latest News:

Dec 11, 2019

PDS Biotechnology Announces Principal Investigator and Independent Data Monitoring Committee for its Phase 2 Clinical Collaboration with Merck

Read More

Dec 11, 2019

PDS Biotechnology Announces Resignation of James Loughlin from Board of Directors

Read More

Dec 03, 2019

PDS Biotechnology to Present at the 12th Annual LD Micro Main Event

Read More

PDS BIOTECHNOLOGY HAS MERGED WITH EDGE THERAPEUTICS

 

ABOUT PDS BIOTECHNOLOGY

PDS Biotechnology is a clinical stage immuno-oncology company with a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

All of PDS’s products are based on the proprietary Versamune® platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.